Metronomic Chemotherapy with 5-fluorouracil and Cisplatin for Inoperable Malignant Bowel Obstruction Because of Peritoneal Dissemination from Gastric Cancer

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2016 Jun 23

PMID 27330361

Citations 2

Authors

S Yang

H Yu

S Li

W Liu

X Liu

H Ma

Affiliations

Soon will be listed here.

Abstract

Background: Gastric cancer is the 2nd leading cause of cancer death worldwide. Malignant bowel obstruction (mbo) is a common complication in advanced gastric cancer because of peritoneal dissemination. A multicentre prospective study reported that patients with peritoneal dissemination of gastric origin survive for a median of 3.1 months. The aim of the present study was therefore to evaluate the efficacy and safety of metronomic combination chemotherapy with 5-fluorouracil and cisplatin in inoperable mbo from peritoneal dissemination in gastric cancer.

Methods: Gastric cancer patients diagnosed with inoperable mbo because of peritoneal dissemination were treated with infusional 5-fluorouracil 300 mg/m(2) daily on days 1-5 and 8-12, and cisplatin 5 mg/m(2) daily on days 1-4 and 8-11 every 3 weeks. The primary endpoint was symptom control (remission of obstruction); the secondary endpoint was symptom control time and survival; the tertiary endpoint was adverse effects.

Results: Between January 2013 and December 2014, 26 patients received the study treatment. Before treatment, 18 patients (69.2%) were nil per os, and 8 (30.8%) could consume liquids. After a mean of 3.3 cycles of the study treatment, just 4 patients (15.4%) was still nil per os. Of the remaining 22 patients, 3 (11.5%) could consume liquids, 7 (26.9%) could consume soft solids, and 12 (46.2%) ate a full diet. The improved ability to eat was statistically significant (p < 0.0001). Median duration of remission from mbo was 105 days. Median survival was 182 days. The 3-month survival rate was 69.2%, and the 6-month survival rate was 53.8%. Treatment was well tolerated, with grade iii toxicities consisting of thrombocytopenia in 1 patient (3.84%) and mucositis in 2 patients (7.7%). No abnormalities in serum creatinine were observed.

Conclusions: Metronomic combination chemotherapy with 5-fluorouracil and cisplatin is well tolerated and shows activity in inoperable mbo because of peritoneal dissemination in gastric cancer. Metronomic combination chemotherapy with 5-fluorouracil and cisplatin provides a rationale for exploring this medical problem in the future.

Citing Articles

Cepharanthine, a regulator of keap1-Nrf2, inhibits gastric cancer growth through oxidative stress and energy metabolism pathway.

Lu Y, Zhu C, Ding Y, Wang B, Zhao S, Lv J Cell Death Discov. 2023; 9(1):450.

PMID: 38086844 PMC: 10716385. DOI: 10.1038/s41420-023-01752-z.

Chemonaïveté in inoperable malignant bowel obstruction.

Boutayeb S, El Ghissassi I, Mrabti H, Errihani H Curr Oncol. 2017; 24(1):e75.

PMID: 28270735 PMC: 5330643. DOI: 10.3747/co.24.3362.

References

OConnor B, Creedon B . Pharmacological treatment of bowel obstruction in cancer patients. Expert Opin Pharmacother. 2011; 12(14):2205-14. DOI: 10.1517/14656566.2011.597382. View

Feuer D, Broadley K . Corticosteroids for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000; (2):CD001219. PMC: 6481479. DOI: 10.1002/14651858.CD001219. View

Roder D . The epidemiology of gastric cancer. Gastric Cancer. 2003; 5 Suppl 1:5-11. DOI: 10.1007/s10120-002-0203-6. View

Zelek L, Laval G, Asselain B . Somatostatin analogs for malignant bowel obstruction resulting from peritoneal carcinomatosis. J Clin Oncol. 2013; 31(19):2519-20. DOI: 10.1200/JCO.2012.48.4634. View

Mariani P, Blumberg J, Landau A, Lebrun-Jezekova D, Botton E, Beatrix O . Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol. 2012; 30(35):4337-43. DOI: 10.1200/JCO.2011.40.5712. View

Pasquier E, Kavallaris M, Andre N . Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol. 2010; 7(8):455-65. DOI: 10.1038/nrclinonc.2010.82. View

Tilney H, Lovegrove R, Purkayastha S, Sains P, Weston-Petrides G, Darzi A . Comparison of colonic stenting and open surgery for malignant large bowel obstruction. Surg Endosc. 2006; 21(2):225-33. DOI: 10.1007/s00464-005-0644-1. View

Kim J, Kim S, Im J, Kim J, Jung H . Comparison of treatment outcomes of endoscopic stenting for colonic and extracolonic malignant obstruction. Surg Endosc. 2012; 27(1):272-7. DOI: 10.1007/s00464-012-2439-5. View

Vives M, Ginesta M, Gracova K, Graupera M, Casanovas O, Capella G . Metronomic chemotherapy following the maximum tolerated dose is an effective anti-tumour therapy affecting angiogenesis, tumour dissemination and cancer stem cells. Int J Cancer. 2013; 133(10):2464-72. DOI: 10.1002/ijc.28259. View

10.

Loven D, Hasnis E, Bertolini F, Shaked Y . Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer. Drug Discov Today. 2012; 18(3-4):193-201. DOI: 10.1016/j.drudis.2012.07.015. View

11.

Adler D, Baron T . Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol. 2002; 97(1):72-8. DOI: 10.1111/j.1572-0241.2002.05423.x. View

12.

Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U . Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013; 49(16):3387-95. DOI: 10.1016/j.ejca.2013.06.038. View

13.

Sadeghi B, Arvieux C, Glehen O, Beaujard A, Rivoire M, Baulieux J . Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000; 88(2):358-63. DOI: 10.1002/(sici)1097-0142(20000115)88:2<358::aid-cncr16>3.0.co;2-o. View

14.

Fontana A, Falcone A, Derosa L, Di Desidero T, Danesi R, Bocci G . Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?. Drugs Aging. 2010; 27(9):689-96. DOI: 10.2165/11537480-000000000-00000. View

15.

Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M . Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010; 17(2):445-53. DOI: 10.1677/ERC-09-0281. View

16.

Feuer D, Broadley K, Shepherd J, Barton D . Surgery for the resolution of symptoms in malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer. Cochrane Database Syst Rev. 2000; (4):CD002764. DOI: 10.1002/14651858.CD002764. View

17.

Nars M, Kaneno R . Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer. 2012; 132(11):2471-8. DOI: 10.1002/ijc.27801. View

18.

Bottini A, Generali D, Brizzi M, Fox S, Bersiga A, Bonardi S . Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol. 2006; 24(22):3623-8. DOI: 10.1200/JCO.2005.04.5773. View

19.

Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D . Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90. DOI: 10.3322/caac.20107. View

20.

Kerbel R, Kamen B . The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer. 2004; 4(6):423-36. DOI: 10.1038/nrc1369. View